Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 2
Started
2024-06-25
Last updated
2024-09-23
Condition(s) studied
Acute Lymphoblastic Leukemia ALL
Investigational drug(s) / intervention(s)
Autologous hematopoietic stem cell transplantation combined with CD19-CART
Autologous hematopoietic stem cell transplantation combined with CD19-CART: Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation
Study summary
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Adult patients with high-risk acute B-lymphoblastic leukemia
* Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared
* Eligible for autologous hematopoietic stem cell transplantation
* No major organ dysfunction
Exclusion Criteria:
* Combined with malignant tumors of other organs
* With a serious infection that is not under control
* Syphilis, AIDS, hepatitis B, hepatitis C, any one of them positive
* Patients who have had an allergic reaction to the drugs used in this study or similar drugs
* Other patients deemed unsuitable for inclusion by the investigators
Primary outcome measure(s)
Relapse rate within 2 years — Time Frame: From autologous hematopoietic stem cell transplantation to 2 years after transplantation
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.